Wuhan Wansheng Biotechnology: difference between revisions
Diff·revision 37 → 38·18:50, 11 Feb 2025
Difference between revision 37 and revision 38 of Wuhan Wansheng Biotechnology. 6 lines changed; the page grew by 844 bytes.
| Revision 37 — 01:51, 5 Feb 2025 StabilityStig (talk) fix arithmetic in worked example 7,542 bytes ±0 | Revision 38 — 18:50, 11 Feb 2025 PurityClaimPia (talk) state the assay for the reference interval 8,386 bytes +844 | ||
|---|---|---|---|
| 55 | '''What that tail means is genuinely contested.''' A large report set will contain more low results than a small one simply by being larger, and a set assembled from purchaser submissions is self-selected in ways that may over- or under-represent poor outcomes: a purchaser who suspects a problem is more likely to test, and a purchaser with a good result is more likely to publish. Neither bias has been quantified, and the article does not claim to know the net direction.{{r|reports,tally}} | 55 | '''What that tail means is genuinely contested.''' A large report set will contain more low results than a small one simply by being larger, and a set assembled from purchaser submissions is self-selected in ways that may over- or under-represent poor outcomes: a purchaser who suspects a problem is more likely to test, and a purchaser with a good result is more likely to publish. Neither bias has been quantified, and the article does not claim to know the net direction.{{r|reports,tally}} |
| 56 | 56 | ||
| + | 57 | The one statement the set does support is comparative in a limited way: the ''dispersion'' of reported figures is wider here than for entities with more standardised certificates. Dispersion is a property of the reports and not necessarily of the material.{{r|usp1503}} | |
| + | 58 | ||
| + | 59 | == Reception == | |
| + | 60 | The PeptidePedia tally records 914 self-reported submissions to July 2026 — toward the lower end among the supplier articles. Recurring positive themes are catalogue breadth, price and the availability of testing data; recurring complaints concern documentation inconsistency and variance between orders.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | |
| + | 61 | ||
| 57 | == References == | 62 | == References == |
| 58 | {{reflist}} | 63 | {{reflist}} |
| ⋮ | ⋮ | ||
| 61 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 66 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 62 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 67 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 68 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 63 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 69 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 64 | 70 |